Verteporfin Photodynamic Therapy for the Treatment of Chorioretinal Conditions: A Narrative Review

References

• Newman DK. Photodynamic therapy: current role in the treatment of chorioretinal conditions. Eye (Lond). 2016;30(2):202–210. doi:10.1038/eye.2015.251
   PubMed Web of Science ®Google Scholar
• van Dijk EHC, van Rijssen TJ, Subhi Y, Boon CJF. Photodynamic therapy for chorioretinal diseases: a practical approach. Ophthalmol Ther. 2020;9(2):329–342. doi:10.1007/s40123-020-00250-0
   PubMed Web of Science ®Google Scholar
• Chowdhary RK, Sharif I, Chansarkar N, et al. Correlation of photosensitizer delivery to lipoproteins and efficacy in tumor and arthritis mouse models; comparison of lipid-based and Pluronic P123 formulations. J Pharm Pharm Sci. 2003;6(2):198–204.
   PubMed Web of Science ®Google Scholar
• Weishaupt KR, Gomer CJ, Dougherty TJ. Identification of singlet oxygen as the cytotoxic agent in photoinactivation of a murine tumor. Cancer Res. 1976;36(7 pt 1):2326–2329.
   PubMed Web of Science ®Google Scholar
• Michels S, Schmidt-Erfurth U. Sequence of early vascular events after photodynamic therapy. Invest Ophthalmol Vis Sci. 2003;44(5):2147–2154. doi:10.1167/iovs.02-0604
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Michels S, Barbazetto I, Laqua H. Photodynamic effects on choroidal neovascularization and physiological choroid. Invest Ophthalmol Vis Sci. 2002;43(3):830–841.
   PubMed Web of Science ®Google Scholar
• Debefve E, Pegaz B, van den Bergh H, Wagnieres G, Lange N, Ballini JP. Video monitoring of neovessel occlusion induced by photodynamic therapy with verteporfin (Visudyne), in the CAM model. Angiogenesis. 2008;11(3):235–243. doi:10.1007/s10456-008-9106-4
   PubMed Web of Science ®Google Scholar
• Kramer M, Miller JW, Michaud N, et al. Liposomal benzoporphyrin derivative verteporfin photodynamic therapy. Selective treatment of choroidal neovascularization in monkeys. Ophthalmology. 1996;103(3):427–438. doi:10.1016/S0161-6420(96)30675-1
   PubMed Web of Science ®Google Scholar
• Miller JW, Walsh AW, Kramer M, et al. Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin. Arch Ophthalmol. 1995;113(6):810–818. doi:10.1001/archopht.1995.01100060136048
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Hasan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol. 2000;45(3):195–214. doi:10.1016/S0039-6257(00)00158-2
   PubMed Web of Science ®Google Scholar
• Husain D, Miller JW, Michaud N, Connolly E, Flotte TJ, Gragoudas ES. Intravenous infusion of liposomal benzoporphyrin derivative for photodynamic therapy of experimental choroidal neovascularization. Arch Ophthalmol. 1996;114(8):978–985. doi:10.1001/archopht.1996.01100140186012
   PubMedGoogle Scholar
• Visudyne (verteporfin for injection), for intravenous use [package insert]. Bridgewater, NJ: Bausch & Lomb Americas Inc.; February 2023.
   Google Scholar
• Desmettre T, Mainster MA, Ledesma-Gil G. Half-fluence, half-dose photodynamic therapy: less direct damage but more inflammation? Pharmaceuticals (Basel). 2023;16(4):494. doi:10.3390/ph16040494
   PubMedGoogle Scholar
• Iacono P, Da Pozzo S, Varano M, Parravano M. Photodynamic therapy with verteporfin for chronic central serous chorioretinopathy: a review of data and efficacy. Pharmaceuticals (Basel). 2020;13(11):349. doi:10.3390/ph13110349
   PubMedGoogle Scholar
• Ledesma-Gil G, Desmettre T, Mainster MA. Bacillary layer detachment after photodynamic therapy for central serous chorioretinopathy. Retin Cases Brief Rep. 2023;17(3):239–241. doi:10.1097/ICB.0000000000001190
   PubMedGoogle Scholar
• Gao Y, Yu T, Zhang Y, Dang G. Anti-VEGF monotherapy versus photodynamic therapy and anti-VEGF combination treatment for neovascular age-related macular degeneration: a meta-analysis. Invest Ophthalmol Vis Sci. 2018;59(10):4307–4317. doi:10.1167/iovs.17-23747
   PubMed Web of Science ®Google Scholar
• Saint-Geniez M, Maldonado AE, D’Amore PA. VEGF expression and receptor activation in the choroid during development and in the adult. Invest Ophthalmol Vis Sci. 2006;47(7):3135–3142. doi:10.1167/iovs.05-1229
   PubMed Web of Science ®Google Scholar
• Moon BH, Kim Y, Kim SY. Twenty years of anti-vascular endothelial growth factor therapeutics in neovascular age-related macular degeneration treatment. Int J Mol Sci. 2023;24(16):13004. doi:10.3390/ijms241613004
   PubMed Web of Science ®Google Scholar
• Helotera H, Kaarniranta K. A linkage between angiogenesis and inflammation in neovascular age-related macular degeneration. Cells. 2022;11(21):3453. doi:10.3390/cells11213453
   PubMed Web of Science ®Google Scholar
• Avaylon J, Gallemore RP. Verteporfin photodynamic therapy for the treatment of choroidal conditions—an overview. US Ophthalmic Rev. 2019;12(2):69–78. doi:10.17925/USOR.2019.12.2.69.
   Google Scholar
• Guymer RH, Campbell TG. Age-related macular degeneration. Lancet. 2023;401(10386):1459–1472. doi:10.1016/S0140-6736(22)02609-5
   PubMed Web of Science ®Google Scholar
• Apte RS. Age-related macular degeneration. N Engl J Med. 2021;385(6):539–547. doi:10.1056/NEJMcp2102061
   PubMed Web of Science ®Google Scholar
• Ferris FL 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984;102(11):1640–1642. doi:10.1001/archopht.1984.01040031330019
   PubMed Web of Science ®Google Scholar
• Rastoin O, Pages G, Dufies M. Experimental models in neovascular age related macular degeneration. Int J Mol Sci. 2020;21(13):4627. doi:10.3390/ijms21134627
   PubMed Web of Science ®Google Scholar
• Song D, Liu P, Shang K, Ma YB. Application and mechanism of anti-VEGF drugs in age-related macular degeneration. Front Bioeng Biotechnol. 2022;10:943915. doi:10.3389/fbioe.2022.943915
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Chong V, Loewenstein A, et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol. 2014;98(9):1144–1167. doi:10.1136/bjophthalmol-2014-305702
   PubMed Web of Science ®Google Scholar
• Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. Arch Ophthalmol. 1999;117(10):1329–1345. doi:10.1001/archopht.117.10.1329
   PubMed Web of Science ®Google Scholar
• Soubrane G, Bressler NM. Treatment of subfoveal choroidal neovascularisation in age related macular degeneration: focus on clinical application of verteporfin photodynamic therapy. Br J Ophthalmol. 2001;85(4):483–495. doi:10.1136/bjo.85.4.483
   PubMed Web of Science ®Google Scholar
• Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2. Am J Ophthalmol. 2001;131(5):541–560. doi:10.1016/s0002-9394(01)00967-9
   PubMed Web of Science ®Google Scholar
• Bressler NM; Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. Arch Ophthalmol. 2001;119(2):198–207.
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–1431. doi:10.1056/NEJMoa054481
   PubMed Web of Science ®Google Scholar
• Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432–1444. doi:10.1056/NEJMoa062655
   PubMed Web of Science ®Google Scholar
• Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;116(1):57–65.e55. doi:10.1016/j.ophtha.2008.10.018
   PubMed Web of Science ®Google Scholar
• Heier JS, Boyer DS, Ciulla TA, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol. 2006;124(11):1532–1542. doi:10.1001/archopht.124.11.1532
   PubMed Web of Science ®Google Scholar
• Antoszyk AN, Tuomi L, Chung CY, Singh A, Group FS. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol. 2008;145(5):862–874. doi:10.1016/j.ajo.2007.12.029
   PubMed Web of Science ®Google Scholar
• Kaiser PK, Boyer DS, Cruess AF, et al. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study. Ophthalmology. 2012;119(5):1001–1010. doi:10.1016/j.ophtha.2012.02.003
   PubMed Web of Science ®Google Scholar
• Larsen M, Schmidt-Erfurth U, Lanzetta P, et al. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results. Ophthalmology. 2012;119(5):992–1000. doi:10.1016/j.ophtha.2012.02.002
   PubMed Web of Science ®Google Scholar
• Gallemore RP, Wallsh J, Hudson HL, Ho AC, Chace R, Pearlman J. Combination verteporfin photodynamic therapy ranibizumab-dexamethasone in choroidal neovascularization due to age-related macular degeneration: results of a phase II randomized trial. Clin Ophthalmol. 2017;11:223–231. doi:10.2147/OPTH.S119510
   PubMed Web of Science ®Google Scholar
• Arepalli S, Kaiser PK. Pipeline therapies for neovascular age related macular degeneration. Int J Retina Vitreous. 2021;7(1):55. doi:10.1186/s40942-021-00325-5
   PubMedGoogle Scholar
• Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537–2548. doi:10.1016/j.ophtha.2012.09.006
   PubMed Web of Science ®Google Scholar
• Takahashi K, Iida T, Ishida S, et al. Effectiveness of current treatments for wet age-related macular degeneration in Japan: a systematic review and pooled data analysis. Clin Ophthalmol. 2022;16:531–540. doi:10.2147/OPTH.S345403
   PubMed Web of Science ®Google Scholar
• Chandra S, McKibbin M, Mahmood S, et al. The Royal College of Ophthalmologists Commissioning guidelines on age macular degeneration: executive summary. Eye (Lond). 2022;36(11):2078–2083. doi:10.1038/s41433-022-02095-2
   PubMed Web of Science ®Google Scholar
• National Institute for Clinical Excellence. Age-related macular degeneration: NICE guideline NG82. 2018; Available from: https://www.nice.org.uk/guidance/ng82. Accessed June 21, 2023.
   Google Scholar
• Vabysmo (faricimab-svoa) injection, for intravitreal use [package insert]. South San Francisco, CA: Genentech, Inc.; October 2023.
   Google Scholar
• Eylea (aflibercept) injection, for intravitreal use [package insert]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc.; August 2023.
   Google Scholar
• Eylea HD (aflibercept) injection, for intravitreal use [package insert]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc.; August 2023.
   Google Scholar
• Anantharaman G, Sheth J, Bhende M, et al. Polypoidal choroidal vasculopathy: pearls in diagnosis and management. Indian J Ophthalmol. 2018;66(7):896–908. doi:10.4103/ijo.IJO_1136_17
   PubMed Web of Science ®Google Scholar
• Ruamviboonsuk P, Lai TYY, Chen SJ, et al. Polypoidal choroidal vasculopathy: updates on risk factors, diagnosis, and treatments. Asia Pac J Ophthalmol (Phila). 2023;12(2):184–195. doi:10.1097/APO.0000000000000573
   PubMed Web of Science ®Google Scholar
• Cheung CMG, Lai TYY, Teo K, et al. Polypoidal choroidal vasculopathy: consensus nomenclature and non-indocyanine green angiograph diagnostic criteria from the Asia-Pacific Ocular Imaging Society PCV Workgroup. Ophthalmology. 2021;128(3):443–452. doi:10.1016/j.ophtha.2020.08.006
   PubMed Web of Science ®Google Scholar
• Cheung CMG, Lai TYY, Ruamviboonsuk P, et al. Polypoidal choroidal vasculopathy: definition, pathogenesis, diagnosis, and management. Ophthalmology. 2018;125(5):708–724. doi:10.1016/j.ophtha.2017.11.019
   PubMed Web of Science ®Google Scholar
• Yamashiro K, Yanagi Y, Koizumi H, et al. Relationship between pachychoroid and polypoidal choroidal vasculopathy. J Clin Med. 2022;11(15):4614. doi:10.3390/jcm11154614
   PubMed Web of Science ®Google Scholar
• Cheung CMG, Lee WK, Koizumi H, Dansingani K, Lai TYY, Freund KB. Pachychoroid disease. Eye (Lond). 2019;33(1):14–33. doi:10.1038/s41433-018-0158-4
   PubMed Web of Science ®Google Scholar
• Koh AH, Chen LJ, Chen SJ, et al. Polypoidal choroidal vasculopathy: evidence-based guidelines for clinical diagnosis and treatment. Retina. 2013;33(4):686–716. doi:10.1097/IAE.0b013e3182852446
   PubMed Web of Science ®Google Scholar
• Silva R, Arias L, Nunes S, et al. Efficacy and safety of intravitreal aflibercept treat and extend for polypoidal choroidal vasculopathy in the ATLANTIC Study: a randomized clinical trial. Ophthalmologica. 2022;245(1):80–90. doi:10.1159/000518235
   PubMed Web of Science ®Google Scholar
• Lim TH, Lai TYY, Takahashi K, et al. Comparison of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: the EVEREST II randomized clinical trial. JAMA Ophthalmol. 2020;138(9):935–942. doi:10.1001/jamaophthalmol.2020.2443
   PubMed Web of Science ®Google Scholar
• Lee WK, Iida T, Ogura Y, et al. Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study: a randomized clinical trial. JAMA Ophthalmol. 2018;136(7):786–793. doi:10.1001/jamaophthalmol.2018.1804
   PubMed Web of Science ®Google Scholar
• Koh A, Lee WK, Chen LJ, et al. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina. 2012;32(8):1453–1464. doi:10.1097/IAE.0b013e31824f91e8
   PubMed Web of Science ®Google Scholar
• Wong TY, Ogura Y, Lee WK, et al. Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy: two-year results of the Aflibercept in Polypoidal Choroidal Vasculopathy Study. Am J Ophthalmol. 2019;204:80–89. doi:10.1016/j.ajo.2019.02.027
   PubMed Web of Science ®Google Scholar
• Cheung CMG, Tan CS, Patalauskaite R, Margaron P, Lai TYY. Ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: predictors of visual and anatomical response in the EVEREST II Study. Retina. 2021;41(2):387–392. doi:10.1097/IAE.0000000000002902
   PubMed Web of Science ®Google Scholar
• Xu TT, Reynolds MM, Hodge DO, Smith WM. Epidemiology and clinical characteristics of presumed ocular histoplasmosis in Olmsted County, Minnesota. Ocul Immunol Inflamm. 2022;30(5):1039–1043. doi:10.1080/09273948.2020.1859549
   PubMed Web of Science ®Google Scholar
• Diaz RI, Sigler EJ, Rafieetary MR, Calzada JI. Ocular histoplasmosis syndrome. Surv Ophthalmol. 2015;60(4):279–295. doi:10.1016/j.survophthal.2015.02.005
   PubMed Web of Science ®Google Scholar
• Benedict K, Shantha JG, Yeh S, Beer KD, Jackson BR. Presumed ocular histoplasmosis syndrome in a commercially insured population, United States. PLoS One. 2020;15(3):e0230305. doi:10.1371/journal.pone.0230305
   PubMed Web of Science ®Google Scholar
• Richey BF, Obrock RS, Gee ZM, Lu DY, Jacobsen GJ, Richards SC. Smoking, rural residence and diabetes as risk factors for presumed ocular histoplasmosis syndrome. Retina. 2022;42(2):369–374. doi:10.1097/IAE.0000000000003322
   PubMed Web of Science ®Google Scholar
• Walia HS, Shah GK, Blinder KJ. Treatment of CNV secondary to presumed ocular histoplasmosis with intravitreal aflibercept 2.0 mg injection. Can J Ophthalmol. 2016;51(2):91–96. doi:10.1016/j.jcjo.2015.11.007
   PubMed Web of Science ®Google Scholar
• Heier JS, Brown D, Ciulla T, et al. Ranibizumab for choroidal neovascularization secondary to causes other than age-related macular degeneration: a phase I clinical trial. Ophthalmology. 2011;118(1):111–118. doi:10.1016/j.ophtha.2010.04.016
   PubMed Web of Science ®Google Scholar
• Dudenhoefer NE, Noble CW, Petersen MR, et al. Intravitreal antivascular endothelial growth factor for the treatment of choroidal neovascularization secondary to ocular histoplasmosis: ten-year follow-up. Retina. 2022;42(8):1568–1573. doi:10.1097/IAE.0000000000003488
   PubMed Web of Science ®Google Scholar
• Saperstein DA, Rosenfeld PJ, Bressler NM, et al. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin in the ocular histoplasmosis syndrome: one-year results of an uncontrolled, prospective case series. Ophthalmology. 2002;109(8):1499–1505. doi:10.1016/S0161-6420(02)01103-X
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Saperstein DA, Bressler NM, et al. Photodynamic therapy with verteporfin in ocular histoplasmosis: uncontrolled, open-label 2-year study. Ophthalmology. 2004;111(9):1725–1733. doi:10.1016/j.ophtha.2004.02.014
   PubMed Web of Science ®Google Scholar
• Ramaiya K, Blinder KJ, Ciulla T, Cooper B, Shah GK. Ranibizumab versus photodynamic therapy for presumed ocular histoplasmosis syndrome. Ophthalmic Surg Lasers Imaging Retina. 2013;44(1):17–21. doi:10.3928/23258160-20121221-07
   PubMed Web of Science ®Google Scholar
• Han DP, McAllister JT, Weinberg DV, Kim JE, Wirostko WJ. Combined intravitreal anti-VEGF and verteporfin photodynamic therapy for juxtafoveal and extrafoveal choroidal neovascularization as an alternative to laser photocoagulation. Eye (Lond). 2010;24(4):713–716. doi:10.1038/eye.2009.122
   PubMed Web of Science ®Google Scholar
• Nemeth J, Tapaszto B, Aclimandos WA, et al. Update and guidance on management of myopia. European Society of Ophthalmology in cooperation with International Myopia Institute. Eur J Ophthalmol. 2021;31(3):853–883. doi:10.1177/1120672121998960
   PubMed Web of Science ®Google Scholar
• Ueta T, Makino S, Yamamoto Y, Fukushima H, Yashiro S, Nagahara M. Pathologic myopia: an overview of the current understanding and interventions. Glob Health Med. 2020;2(3):151–155. doi:10.35772/ghm.2020.01007
   PubMedGoogle Scholar
• Ohno-Matsui K, Lai TY, Lai CC, Cheung CM. Updates of pathologic myopia. Prog Retin Eye Res. 2016;52:156–187. doi:10.1016/j.preteyeres.2015.12.001
   PubMed Web of Science ®Google Scholar
• Wolf S, Balciuniene VJ, Laganovska G, et al. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology. 2014;121(3):682–692.e682. doi:10.1016/j.ophtha.2013.10.023
   PubMed Web of Science ®Google Scholar
• Jutley G, Jutley G, Tah V, Lindfield D, Menon G. Treating peripapillary choroidal neovascular membranes: a review of the evidence. Eye (Lond). 2011;25(6):675–681. doi:10.1038/eye.2011.24
   PubMed Web of Science ®Google Scholar
• Wilde C, Poostchi A, Mehta RL, et al. Prevalence of peripapillary choroidal neovascular membranes (PPCNV) in an elderly UK population-the Bridlington eye assessment project (BEAP): a cross-sectional study (2002-2006). Eye (Lond). 2019;33(3):451–458. doi:10.1038/s41433-018-0232-y
   PubMed Web of Science ®Google Scholar
• Bernstein PS, Horn RS. Verteporfin photodynamic therapy involving the optic nerve for peripapillary choroidal neovascularization. Retina. 2008;28(1):81–84. doi:10.1097/IAE.0b013e31815e9351
   PubMed Web of Science ®Google Scholar
• Stanescu N, Friehmann A, Nemet A, et al. Long-term outcomes of anti-vascular endothelial growth factor treatment in peripapillary choroidal neovascularisation due to age-related macular degeneration. Eye (Lond). 2023;37(6):1202–1206. doi:10.1038/s41433-022-02089-0
   PubMed Web of Science ®Google Scholar
• Liegl R, Ulbig MW. Central serous chorioretinopathy. Ophthalmologica. 2014;232(2):65–76. doi:10.1159/000360014
   PubMed Web of Science ®Google Scholar
• Zhang X, Lim CZF, Chhablani J, Wong YM. Central serous chorioretinopathy: updates in the pathogenesis, diagnosis and therapeutic strategies. Eye Vis (Lond). 2023;10(1):33. doi:10.1186/s40662-023-00349-y
   PubMedGoogle Scholar
• van Rijssen TJ, van Dijk EHC, Yzer S, et al. Central serous chorioretinopathy: towards an evidence-based treatment guideline. Prog Retin Eye Res. 2019;73:100770. doi:10.1016/j.preteyeres.2019.07.003
   PubMed Web of Science ®Google Scholar
• Moreno-Morillo FJ, Fernández-Vigo JI, Burgos-Blasco B, Moriche-Carretero M, López-Guajardo L, Donate-López J. Utility of an additional photodynamic therapy session after multiple failed PDT treatments in chronic central serous chorioretinopathy. Photodiagnosis Photodyn Ther. 2022;39:102953. doi:10.1016/j.pdpdt.2022.102953
   PubMed Web of Science ®Google Scholar
• Reynolds ME, Karesh JW, Oh GT, Stahlman S. Incident and recurrent cases of central serous chorioretinopathy, active component, U.S. Armed Forces, 2001-2018. MSMR. 2019;26(9):31–34.
   PubMedGoogle Scholar
• Goté JT, Singh SR, Chhablani J. Comparing treatment outcomes in randomized controlled trials of central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2023;261(8):2135–2168. doi:10.1007/s00417-023-05996-4
   PubMed Web of Science ®Google Scholar
• Mohabati D, van Rijssen TJ, van Dijk EH, et al. Clinical characteristics and long-term visual outcome of severe phenotypes of chronic central serous chorioretinopathy. Clin Ophthalmol. 2018;12:1061–1070. doi:10.2147/OPTH.S160956
   PubMed Web of Science ®Google Scholar
• Park DG, Jeong S, Noh D, Sagong M. Optimal fluence rate of photodynamic therapy for chronic central serous chorioretinopathy. Br J Ophthalmol. 2021;105(6):844–849. doi:10.1136/bjophthalmol-2020-316837
   PubMed Web of Science ®Google Scholar
• Aisu N, Miyake M, Hosoda Y, et al. Effectiveness of reduced-fluence photodynamic therapy for chronic central serous chorioretinopathy: a propensity score analysis. Ophthalmol Sci. 2022;2(2):100152. doi:10.1016/j.xops.2022.100152
   PubMedGoogle Scholar
• Cheng CK, Chang CK, Peng CH. Comparison of photodynamic therapy using half-dose of verteporfin or half-fluence of laser light for the treatment of chronic central serous chorioretinopathy. Retina. 2017;37(2):325–333. doi:10.1097/IAE.0000000000001138
   PubMed Web of Science ®Google Scholar
• Park W, Kim M, Kim RY, Park YH. Comparing effects of photodynamic therapy in central serous chorioretinopathy: full-dose versus half-dose versus half-dose-half-fluence. Graefes Arch Clin Exp Ophthalmol. 2019;257(10):2155–2161. doi:10.1007/s00417-019-04426-8
   PubMed Web of Science ®Google Scholar
• Park YJ, Kim YK, Park KH, Woo SJ. Long-term efficacy and safety of photodynamic therapy in patients with chronic central serous chorioretinopathy. Ophthalmic Surg Lasers Imaging Retina. 2019;50(12):760–770. doi:10.3928/23258160-20191119-03
   PubMed Web of Science ®Google Scholar
• van Rijssen TJ, van Dijk EHC, Tsonaka R, et al. Half-dose photodynamic therapy versus eplerenone in chronic central serous chorioretinopathy (SPECTRA): a randomized controlled trial. Am J Ophthalmol. 2022;233:101–110. doi:10.1016/j.ajo.2021.06.020
   PubMed Web of Science ®Google Scholar
• Feenstra HMA, van Dijk EHC, van Rijssen TJ, et al. Long-term follow-up of chronic central serous chorioretinopathy patients after primary treatment of oral eplerenone or half-dose photodynamic therapy and crossover treatment: SPECTRA trial report No. 3. Graefes Arch Clin Exp Ophthalmol. 2023;261(3):659–668. doi:10.1007/s00417-022-05836-x
   PubMed Web of Science ®Google Scholar
• Christou EE, Katsanos A, Georgalas I, Kozobolis V, Kalogeropoulos C, Stefaniotou M. The choroid after half-dose photodynamic therapy in chronic central serous chorioretinopathy. Acta Medica (Hradec Kralove). 2022;65(3):89–98. doi:10.14712/18059694.2022.24
   PubMedGoogle Scholar
• Hu YC, Chen YL, Chen YC, Chen SN. 3-year follow-up of half-dose verteporfin photodynamic therapy for central serous chorioretinopathy with OCT-angiography detected choroidal neovascularization. Sci Rep. 2021;11(1):13286. doi:10.1038/s41598-021-92693-z
   PubMed Web of Science ®Google Scholar
• Hurley DJ, Gallagher D, Petronzi V, O’Rourke M, Kinsella F, Townley D. Examining the efficacy of verteporfin photo-dynamic therapy (PDT) at different dose & fluence levels. Photodiagnosis Photodyn Ther. 2023;44:103848. doi:10.1016/j.pdpdt.2023.103848
   PubMed Web of Science ®Google Scholar
• Feenstra HMA, van Dijk EHC, van Rijssen TJ, et al. Crossover to half-dose photodynamic therapy or eplerenone in chronic central serous chorioretinopathy patients. Ophthalmol Retina. 2022;6(10):930–938. doi:10.1016/j.oret.2022.04.014
   PubMedGoogle Scholar
• Funatsu R, Terasaki H, Sonoda S, Shiihara H, Mihara N, Sakamoto T. Characteristics related to visual acuity loss after successful photodynamic therapy for eyes with central serous chorioretinopathy. Am J Ophthalmol. 2023;256:P164–P174.
   PubMed Web of Science ®Google Scholar
• Ho M, Lai FHP, Ng DSC, et al. Analysis of choriocapillaris perfusion and choroidal layer changes in patients with chronic central serous chorioretinopathy randomised to micropulse laser or photodynamic therapy. Br J Ophthalmol. 2021;105(4):555–560. doi:10.1136/bjophthalmol-2020-316076
   PubMed Web of Science ®Google Scholar
• Kretz FTA, Beger I, Koch F, Nowomiejska K, Auffarth GU, Koss MJ. Randomized clinical trial to compare micropulse photocoagulation versus half-dose verteporfin photodynamic therapy in the treatment of central serous chorioretinopathy. Ophthalmic Surg Lasers Imaging Retina. 2015;46(8):837–843. doi:10.3928/23258160-20150909-08
   PubMed Web of Science ®Google Scholar
• van Dijk EHC, Fauser S, Breukink MB, et al. Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: the PLACE Trial. Ophthalmology. 2018;125(10):1547–1555. doi:10.1016/j.ophtha.2018.04.021
   PubMed Web of Science ®Google Scholar
• Russo A, Turano R, Morescalchi F, et al. Comparison of half-dose photodynamic therapy and 689 nm laser treatment in eyes with chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2017;255(6):1141–1148. doi:10.1007/s00417-017-3626-9
   PubMed Web of Science ®Google Scholar
• Pérez-González D, Goldstein M, Iglicki M, Zur D. Half-dose photodynamic therapy as a novel treatment protocol for circumscribed choroidal hemangioma. Life (Basel). 2022;12(11):1748. doi:10.3390/life12111748
   PubMed Web of Science ®Google Scholar
• Kumar A, Shankar S, Singh A, Mishra S, Kumar P, Arora A. Photodynamic therapy in the treatment of circumscribed choroidal hemangioma: current perspectives. Photodiagnosis Photodyn Ther. 2022;39:103000. doi:10.1016/j.pdpdt.2022.103000
   PubMed Web of Science ®Google Scholar
• Murro V, Mucciolo DP, Giorgio D, et al. Long-term follow-up and “double layer sign” in patients affected by circumscribed choroidal hemangioma. Photodiagnosis Photodyn Ther. 2020;31:101960. doi:10.1016/j.pdpdt.2020.101960
   PubMed Web of Science ®Google Scholar
• Shields CL, Dalvin LA, Lim LS, et al. Circumscribed choroidal hemangioma: visual outcome in the pre-photodynamic therapy era versus photodynamic therapy era in 458 cases. Ophthalmol Retina. 2020;4(1):100–110. doi:10.1016/j.oret.2019.08.004
   PubMedGoogle Scholar
• Jurklies B, Anastassiou G, Ortmans S, et al. Photodynamic therapy using verteporfin in circumscribed choroidal haemangioma. Br J Ophthalmol. 2003;87(1):84–89. doi:10.1136/bjo.87.1.84
   PubMed Web of Science ®Google Scholar
• Karaca BO, Türkoğlu EB, Doğan ME. Long term results of photodynamic therapy in intraocular tumors. Photodiagnosis Photodyn Ther. 2023;42:103564. doi:10.1016/j.pdpdt.2023.103564
   PubMed Web of Science ®Google Scholar
• Di Nicola M, Williams BK, Srinivasan A, et al. Photodynamic therapy for circumscribed choroidal hemangioma in 79 consecutive patients: comparative analysis of factors predictive of visual outcome. Ophthalmol Retina. 2020;4(10):1024–1033. doi:10.1016/j.oret.2020.04.018
   PubMedGoogle Scholar
• Namba M, Shiode Y, Morizane Y, et al. Successful resolution of Coats disease by photodynamic therapy: a case report. BMC Ophthalmol. 2018;18(1):264. doi:10.1186/s12886-018-0930-z
   PubMedGoogle Scholar
• Dave V, Chhablani J, Narayanan R. Different treatment modalities for choroidal neovascularization in two eyes of one patient with bilateral type 2A parafoveal telangiectasia. Indian J Ophthalmol. 2013;61(7):353–355. doi:10.4103/0301-4738.99851
   PubMed Web of Science ®Google Scholar
• Cheng JY, Adrian KH. Photodynamic therapy for choroidal neovascularization in stargardt disease and retinitis pigmentosa. Retin Cases Brief Rep. 2009;3(4):388–390. doi:10.1097/ICB.0b013e31817f2e3f
   PubMedGoogle Scholar